title: Serum proBDNF/BDNF and response to fluvoxamine in drug-naïve first-episode major depressive disorder patients.
abstract: BACKGROUND
  We investigated the association between serum proBDNF, a precursor of brain-derived neurotrophic factor (BDNF), and response to fluvoxamine in patients with major depressive disorder (MDD) using the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR): physically healthy and free of current alcohol or drug abuse, comorbid anxiety, or personality disorders.
  
  
  METHODS
  Fifty-one patients with MDD (M/F, 19:32; age, 38 ± 19 years) and 51 healthy controls (M/F, 22:29; age, 34 ± 17 years) were studied using DSM-IV-TR: physically healthy and free of current alcohol or drug abuse, comorbid anxiety, or personality disorders. Serum levels of proBDNF and MDNF were measured by sandwich enzyme-linked immunosorbent assay (ELISA).
  
  
  RESULTS
  Serum mature BDNF levels in the MDD patients were significantly lower than those in the healthy controls (t = 3.046, p = 0.0018). On the other hand, no difference was found in serum proBDNF between the MDD patients and the healthy controls (t = -0.979, p = 0.833). A trend of negative correlation was found between baseline serum BDNF and baseline scores of the 17 items of the Hamilton Rating Scale for Depression (HAMD17) (r = -0.183, p = 0.071). No correlation was however found between HAMD17 scores and proBDNF at baseline (r = 0.092, p = 0.421). Furthermore, no correlation was observed between baseline HAMD17 scores and baseline proBDNF/BDNF (r = -0.130, p = 0.190). No changes were observed in serum levels of proBDNF and BDNF during the treatment periods.
  
  
  CONCLUSIONS
  These results suggest that there is no association between serum proBDNF/BDNF and fluvoxamine response in MDD patients at least within 4 weeks of the treatment.
authors.affiliation: Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan.
authors.forename: Reiji
authors.initials: R
authors.lastname: Yoshimura
authors.affiliation: Department of Psychiatry, Fujita Health University, Toyoake 470-1192, Japan.
authors.forename: Taro
authors.initials: T
authors.lastname: Kishi
authors.affiliation: Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan.
authors.forename: Hikaru
authors.initials: H
authors.lastname: Hori
authors.affiliation: Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan.
authors.forename: Kiyokazu
authors.initials: K
authors.lastname: Atake
authors.affiliation: Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan.
authors.forename: Asuka
authors.initials: A
authors.lastname: Katsuki
authors.affiliation: Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan.
authors.forename: Wakako
authors.initials: W
authors.lastname: Nakano-Umene
authors.affiliation: Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan.
authors.forename: Atsuko
authors.initials: A
authors.lastname: Ikenouchi-Sugita
authors.affiliation: Department of Psychiatry, Fujita Health University, Toyoake 470-1192, Japan.
authors.forename: Nakao
authors.initials: N
authors.lastname: Iwata
authors.affiliation: Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan.
authors.forename: Jun
authors.initials: J
authors.lastname: Nakamura
keywords: BDNF; Fluvoxamine; Major depressive disorder; Serum; proBDNF
references.citation: World J Biol Psychiatry. 2010 Sep;11(6):763-73
references.pmid: 20334574
references.citation: J Affect Disord. 2014 May;160:1-9
references.pmid: 24709015
references.citation: PLoS One. 2013 Nov 25;8(11):e75362
references.pmid: 24282498
references.citation: World J Biol Psychiatry. 2009;10(4 Pt 2):620-2
references.pmid: 18609433
references.citation: Mol Psychiatry. 2011 Sep;16(9):960-72
references.pmid: 20733577
references.citation: PLoS One. 2012;7(8):e42676
references.pmid: 22880079
references.citation: Psychiatry Clin Neurosci. 2010 Aug;64(4):341-57
references.pmid: 20653908
references.citation: Biol Psychiatry. 2008 Sep 15;64(6):527-32
references.pmid: 18571629
references.citation: Transl Neurosci. 2013 Mar 1;4(1):46-58
references.pmid: 23691270
references.citation: Mol Psychiatry. 2014 Jul;19(7):750-1
references.pmid: 24342989
references.citation: Neuropsychiatr Dis Treat. 2009;5:433-49
references.pmid: 19721723
references.citation: J Affect Disord. 2013 Sep 25;150(3):776-84
references.pmid: 23537780
references.citation: Neuropsychiatr Dis Treat. 2005 Dec;1(4):289-99
references.pmid: 18568110
references.citation: Neuropsychiatr Dis Treat. 2013;9:1417-25
references.pmid: 24092979
references.citation: Biol Pharm Bull. 2010;33(12):1999-2002
references.pmid: 21139240
references.citation: Eur Arch Psychiatry Clin Neurosci. 2010 Oct;260(7):527-33
references.pmid: 20306200
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):1022-5
references.pmid: 21338649
references.citation: JAMA Psychiatry. 2013 Nov;70(11):1171-80
references.pmid: 24026579
references.citation: J Psychopharmacol. 2009 Jul;23(5):539-50
references.pmid: 18562407